Embracing Differences: Our journey to diversity, equity, and inclusion
Embracing Differences: Our journey to diversity, equity, and inclusion
Search
Phase III EMPA-KIDNEY trial will stop early
The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
The Urgency for Heart Failure Research and New Treatment Options
The Urgency for Heart Failure Research and New Treatment Options
Ways we’re protecting the planet
Click here to read a few examples of the sustainability practices we’ve put in place at our U.S. HQ, to protect the planet for a more sustainable tomorrow.
IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
200 employees make a difference with record-breaking volunteer efforts
200 employees make a difference with record-breaking volunteer efforts
Biosimilars
Biosimilars
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Onboarding
Onboarding
Celebrating the power of people and their experiences: Observations for Hispanic/ Latinx Heritage Month
Our Boehringer colleagues share how their experiences with their culture have influenced their approach to life and work.
Poultry vaccine site in Georgia continues to reduce carbon emissions
Going carbon neutral has resulted in measurable, positive impacts. From 2021 to 2022, the Gainesville site reduced its CO2 emissions by 23 percent – nearly 700 fewer tons of CO2 emissions are released into the atmosphere
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
FDA accepts Jardiance sNDA for T2D in children 10 and older
The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes
Partnering in CardioMetabolic Diseases
Partnering in CardioMetabolic Diseases
Sunshine Act Compliance
Sunshine Act Compliance
Consumer Health Data Privacy Statement
This Consumer Health Data Privacy Statement applies to “Consumer Health Data,” as that term has been defined under applicable law.
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Regulatory Affairs
Read more on BI's two-year fellowship within Regulatory Affairs. The Fellow will obtain in-depth and hands-on experience in regulatory strategy.
Immunology
Immunology
A legacy in the making: Working together to spark meaningful change
Discover Jim’s passion for being an advocate for meaningful causes.
SPEVIGO approved for expanded indications in China and the US
FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg
Ordering your medicine online? Find a safe pharmacy first.
Learn what to look for when buying medication and how to verify your pharmacy.
An Employee’s Commitment to Ensuring Access to Medicines
An Employee’s Commitment to Ensuring Access to Medicines